| Autor: |
Dan, Wu, Yanyang, Zhang, Lin, Tang, Fuzhen, Wang, Ying, Ye, Chao, Ma, Hui, Zheng, Wenzhou, Yu, Lei, Cao, Yifan, Song, Abuduwaili, Reyimu, Xiaoxiao, Zhang, Haifeng, Wang, Yifei, Nie, Mingxia, Lu, Muge, Qi, Jun, Li, Ruolin, Wang, Kaichao, Yang, Changshuang, Wang, Lawrence Everett, Rodewald, Geroge Fu, Gao, Zhijie, An, Zundong, Yin |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
China CDC weekly. 4(4) |
| ISSN: |
2096-7071 |
| Popis: |
Effectiveness of China's 2 inactivated vaccines (BBIBP-CorV and CoronaVac) against pre-Delta severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants ranged from 47% to over 90%, depending on the clinical endpoint, and with greater effectiveness against more severe coronavirus disease 2019 (COVID-19). During an outbreak in Guangdong, inactivated vaccine effectiveness (VE) against the Delta variant was 70% for symptomatic infection and 100% for severe COVID-19. However, separate or combined VE estimates for the two inactivated vaccines against Delta are not available.In an outbreak that started in a hospital, VEs of completed primary vaccination with inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant were 51%, 61%, and 82%. Completed primary vaccination reduced the risk of progressing from mild to moderate or severe COVID-19 by 74%. VE estimates for BBIBP-CorV and CoronaVac or combined vaccination were similar, and partial vaccination was ineffective.Completed primary vaccination with either of the 2 inactivated COVID-19 vaccines reduces risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Completion of the completed primary vaccination with two doses is necessary for protection from Delta. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
